ABSTRACT: Cell monolayers underpin the discovery and screening of new drugs and allow for fundamental studies of cell biology and disease. However, current cryopreservation technologies do not allow cells to be stored frozen while attached to tissue culture plastic. Hence, cells must be thawed from suspension, cultured for several days or weeks, and finally transferred into multiwell plates for the desired application. This inefficient process consumes significant time handling cells, rather than conducting biomedical research or other value-adding activities. Here, we demonstrate that a synthetic macromolecular cryoprotectant enables the routine, reproducible, and robust cryopreservation of biomedically important cell monolayers, within industry-standard tissue culture multiwell plates. The cells are simply thawed with media and placed in an incubator ready to use within 24 h. Post-thaw cell recovery values were >80% across three cell lines with low well-to-well variance. The cryopreserved cells retained healthy morphology, membrane integrity, proliferative capacity, and metabolic activity; showed marginal increases in apoptotic cells; and responded well to a toxicological challenge using doxorubicin. These discoveries confirm that the cells are “assay-ready” 24 h after thaw. Overall, we show that macromolecular cryoprotectants can address a long-standing cryobiological challenge and offers the potential to transform routine cell culture for biomedical discovery.

INTRODUCTION

Convenient, ready-to-use from the freezer, cell-based assays could accelerate and simplify the discovery of pharmaceutically active compounds, biocompatibility testing, assay development, and discovery of cell signaling and disease pathways. Cryopreservation enables the long-term storage of cells to prevent phenotypic drift associated with continuous culture and allows the distribution of standardized cells around the globe. However, the cold stress of cryopreservation can lead to cell death as described by Mazur’s two-factor hypothesis. This includes excessive dehydration by slow freezing, due to excessive exposure to high salt concentrations from residual unfrozen water, and intracellular ice formation (IIF) (and recrystallization during slow warming) during rapid freezing. To mitigate the damage caused during cryopreservation, a cryoprotective agent (CPA) is essential, with DMSO (dimethyl sulfoxide) being the most widely used cryoprotectant for nucleated mammalian cells. During typical slow-freezing cryopreservation (1 °C min⁻¹), as cellular dehydration occurs, DMSO replaces lost water to reduce cell death from excessive dehydration and IIF. DMSO also minimizes osmotic shock by reducing electrolyte concentration in residual unfrozen solution during freezing.

Mammalian cells are typically cryopreserved in suspension, which often gives high yields, however for most laboratory-based applications (such as toxicity or uptake screening) cells are used as adherent monolayers, thus, creating a mismatch between the format used for storage and that used to generate data. From suspension, cryopreserved cells must be thawed, seeded, and propagated through several flasks until enough...
cells can be plated into well plates for the desired application. Hence, a cell biologist is required to devote a large portion of their time to cell preparation, approximately 1–3 weeks depending on the cell proliferation rates. In essence, more time is spent “handling” the cells rather than conducting research or “value-adding” activities with the cells. The routine handling of different cell lines (e.g., to look for a toxic response or drug delivery) can require time, financial resources, and extensive cell culture knowledge to establish, such as optimum confluency for activity and substrate specificity.

A (deceptively) simple solution to the abovementioned challenges would be to cryopreserve cells directly in microwell plate substrates. In an ideal world, cells could be removed from cold storage in an “assay-ready” format, thawed, and used 24 h post-thaw, removing weeks of laboratory researcher time, facilitating high-throughput screening, and ensuring phenotypically identical cells. Furthermore, highly desirable characteristics of adherent cells could be preserved, including neuron networks and tight cellular junctions. However, in these systems, vitrification is often required to achieve high cell recovery, necessitating significant volumes of organic solvent cryoprotectants, such as 6.5 M ethylene glycol. The broad applicability of the ampholyte scaffold has been shown by deploying backbones with mixed charged side-chains, with reports suggesting that either excess anionic or 1:1 anionic/cationic groups yield the strongest cryoprotective activity. Bailey et al. introduced a synthetically scalable polyampholyte based on the ring open polymerization poly(methyl vinyl ether-alt-maleic anhydride). The use of a maleic anhydride-containing polymer ensures a 1:1 ratio of cationic to anionic groups, unlike heterogeneous materials based on random copolymerization or carbonylation of PLL. This polyampholyte enhanced the post-thaw recovery of a panel of cell lines (A549, MC-3T3, and Neuro-2a cells) compared to DMSO alone and the suspension cryopreservation of stem cells. Despite these advances, there is still no demonstration that cells frozen as monolayers are “assay ready”, whereby they can be removed from the freezer and, with minimal user intervention, be ready to use. To achieve this, an in-depth analysis of cellular health and function is required and the cell lines selected should be of crucial importance to toxicological or screening assays (such as liver cells) to have a significant impact.

Herein, we demonstrate that the polyampholyte derived from poly(methyl vinyl ether-alt-maleic anhydride) and dimethylamino ethanol enables near-quantitative recovery of intact and viable cell monolayers 24 h following removal from a −80 °C freezer, with minimal processing and handling. High cell recovery was demonstrated for adherent cell lines that are widely used in the drug discovery field including A549, HepG2, and Caco-2 cells. Banked “assay-ready” cells were frozen at multiple cell densities, designed for adaptability toward desired applications, and could be stored for over 1 month in a conventional −80 °C freezer. A large panel of post-thaw proliferation, metabolic, membrane integrity, apoptosis, cell cycle, and morphological analyses confirmed that cell monolayers are healthy, function as normal, and are “assay ready”. Finally, a model drug screening test was undertaken using doxorubicin, a chemotherapeutic drug. Our work demonstrates that adherent cells can be cryopreserved so that they are “assay ready” direct from the freezer with minimal handling, facilitating the drug discovery process and reducing the significant time burden associated with routine cell culture.

## EXPERIMENTAL SECTION

**Materials.** Poly(methyl vinyl ether-alt-maleic anhydride) (M, ≈ 80 kDa), tetrahydrofuran (THF), dimethylamino ethanol, deuterium oxide (D2O), type I solution from rat tail, doxorubicin hydrochloride (98%), Eagle’s minimum essential media (MEM), fetal bovine serum (FBS) (non-USA origin), MEM nonessential amino acid (NEAA) solution (100x), 0.4% Trypan blue, dimethyl sulfoxide Hybri-Max, and RNase A from bovine pancreas were purchased from Merck (Gillingham, UK). Dulbecco phosphate-buffered saline (DPBS), Ham’s F-12K (Kaihni’s) medium (F-12K), Antibiotic–Antimycotic (100x) (PSA), Trypsin–EDTA (0.25%), CellEvent Caspase-3/7 Detection Reagent, Live/Dead Viability/Cytotoxicity Kit for mammalian cells, phenol-free DMEM/F-12, and propidium iodide (98%) were purchased from Sigma (St Louis, MO). Resazurin tablets were purchased from Scientific Laboratory Supplies (Nottingham, UK). P450-Glo CYP3A4 Assay and P450-Glo CYP2C9 Assay were purchased from Promega (Wisconsin, USA).

**Physical and Analytical Methods.** Nuclear Magnetic Resonance Spectroscopy. 1H and 13C NMR spectra were recorded on a Bruker HD-400 spectrometer, operating at 293 K using deuterated solvents purchased from Sigma-Aldrich. Chemical shifts were reported as δ in parts per million (ppm) relative to residual nondeuterated...
solvent resonances (\(\text{D}_2\text{O}^\text{1H}: 6 = 4.71\text{ ppm}\)), Bruker Topspin 3.5 Software was used to process and export spectra.

**Infrared Spectroscopy.** FTIR spectra were acquired using an Agilent Cary 630 FTIR (Agilent Technologies, Connecticut, USA) spectrometer equipped with a single reflection diamond ATR accessory with a 45° angle of incidence, a 1 mm diameter sampling surface (200 \(\mu\text{m}\) active area), and a rotating pressure clamp (applying maximum pressure). Scans (128) were obtained of dried, crushed samples between 4000 and 650 cm\(^{-1}\) with a spectral resolution <2 cm\(^{-1}\), wavenumber accuracy of 0.05 cm\(^{-1}\), and wavenumber reproducibility of 0.005 cm\(^{-1}\). Gain, aperture, scan speed, and filter were all set to auto. Agilent MicroLab Software, version B05.4, was used to process and export spectra.

**Microscopy.** An Olympus CX41 microscope equipped with a UIS-2 20\(\times\)/0.45/∞/0-2/FN22 lens and blue and green excitation lasers were used for imaging. Image processing was completed using ImageJ (v1.52).

**Flow Cytometry.** A BD Accuri C6, equipped with 488 (solid) and 640 (diode) nm lasers and 533/30, 585/40, and 670 LP filters, was used for flow cytometry experiments. Instrument calibration was completed using BD Biosciences CS&T beads. Maintenance was completed with BD Biosciences cleaning solutions. All samples were completed using BD Biosciences CS&T beads. Maintenance was described cryopreservation method was used for the banking of cells (Tukey’s post hoc test).

**Cryomicroscopy.** Intracellular ice growth was assessed as described previously. Cells were seeded on a 14 mm round glass coverslip at a density of 1 \(\times\) 10\(^5\) cells \(\text{mL}^{-1}\). The coverslip of adhered cells was dissolved 1 tablet (Scientific 300 Laboratory Supplies, CHE3158) in 100 mL) was placed on a Linkam BCS 196 cryostage (Linkam Scientific Instruments, Salford, UK). Cells were incubated at 20 °C for 10 min, to achieve equilibrium, frozen at −40 °C at 1−5 °C min\(^{-1}\), and warmed to RT at 20 °C/min. Lynkis 32 software was used to control the cryostage parameters. All images were captured using an Olympus CX41 microscope equipped with a UIS-2 20\(\times\)/0.45/∞/0-2/FN22 lens (Olympus Ltd.) and a Canon EOS 50D SLR digital camera. Image processing was completed using ImageJ (v1.52).

**Osmolality Measurement.** An Osmomat 3000 (Gonotec, Berlin, Germany) freezing point depression osmometer was used to test osmolality. The two-point instrument calibration was completed with distilled water possessing an osmolality of 300 mosmol kg\(^{-1}\) and sodium chloride solution, with an osmolality of 2000 mOsmol kg\(^{-1}\). Solutions containing cell culture media, 10% FBS, 10% DMSO, and/or 40 mg mL\(^{-1}\) of polyampholyte were subsequently measured.

**Cryoprotective Polyampholyte Synthesis.** The polyampholyte was synthesized as described by Bailey et al., at a larger scale. Poly(methyl vinyl ether-alt-maleic anhydride) with an average \(M_\text{n} \approx 80\text{ kDa} (10^5)\) was stirred in THF (100 mL) and heated to 50 °C until dissolved. After dissolution, dimethylamino ethanol (\(~10^5\) g) was added in excess, with the mixture turning from clear colorless to a pink waxy solid. Following 30 min, the waxy solid was dissolved in water (100 mL) and left to stir overnight. The resulting THF was removed under vacuum, and the resulting solution was purified by dialysis tubing (Spectra/Por, 12−14 kDa MWCO) for 72 h with 6 water changes. The resulting solution was freeze-dried to form a white solid, which was analyzed using \(^1\text{H}\) and \(^{13}\text{C}\) NMR (in \(\text{D}_2\text{O}\)) and IR spectroscopy. Polyampholyte solutions in \(\text{D}_2\text{O}\) were analyzed after 3 months to determine potential degradation routes.

\(^1\text{H}\) NMR (300 MHz, \(\text{D}_2\text{O}\)) \(\delta\) ppm: 4.71 ppm (\(\text{D}_2\text{O}\) solvent peak, s), 4.38 ppm (CH\(_2\)−O−CH\(_2\) br s, 2H), 3.81 ppm (COOH−CH\(_2\) br s, 2H), 3.67 ppm (dioxane internal standard peak, s), 3.39 ppm (backbone CH=CH−CH=CH−N br s, 3H), 3.18 ppm (OCH=CH=CH\(_2\) t, 2.86 (O−CH\(_2\) s), 2.82 ppm (N−(CH\(_2\)\(_3\)) s), 1.77 ppm (backbone CH=CH−CH=CH−br s, 2H), 0.78 ppm (end group CH\(_3\)(s, t). \(^{13}\text{C}\) NMR (300 MHz, \(\text{D}_2\text{O}\)) \(\delta\) ppm: 66.6 ppm (dioxane internal standard peak), 58.8 ppm (HCOO−CH\(_2\)), 55.3 ppm (CH−N(CH\(_3\))(s), 43.1 ppm (CH−COOH), 42.8 ppm (CH\(_2\)(s))−N, 1R ν cm\(^{-1}\): 3650−2940 cm\(^{-1}\) (br w, O−H acid stretch), 1724 cm\(^{-1}\) (s, C=O stretch), 1560 cm\(^{-1}\) (w, O=C−O− carbamate), 1342 cm\(^{-1}\) (w, C−N stretch), 1225 cm\(^{-1}\) (w, C−O stretch).

**Cell Culture.** Human Caucasian lung carcinoma cells (A549, ATCC) were cultured in Ham’s F-12K (Kaighn’s) medium (F-12K) supplemented with 10% FBS and 100 units mL\(^{-1}\) penicillin, 100 μg mL\(^{-1}\) streptomycin, and 250 ng mL\(^{-1}\) amphotericin B (1% PSA). Human liver hepatocellular carcinoma cells (HepG2, ECACC 85011430) were cultured in Eagle’s MEM supplemented with 10% FBS, 1% NEAA, and 1% PSA. Human Caucasian colon adenocarcinoma cells (CaCo-2, ECACC 86010202) were cultured in MEM media supplemented with 20% FBS and 1% PSA. Cells were incubated at 37 °C and 5% CO\(_2\) and passed every 3−4 days, before reaching 70−80% confluency. Cells were dissociated using a balanced salt solution containing trypsin (0.25%) and EDTA (1 mM).

**Cryopreservation of “Assay-ready” Cells in 2-D Monolayers.** **Confluent Monolayer Freezing.** A549 (300k/well), HepG2 (400k/well), and CaCo-2 (150k/well) cells were seeded on 24 well plates (Greiner Bio-one, 662160). HepG2 and CaCo-2 cells were seeded onto collagen (Type I solution from rat tail Merck, C3867) coated plates. Cells were incubated to allow attachment to the substrate (24 h for A549 and HepG2, 48 h for CaCo-2). Cell media was removed, and cells were incubated at RT with 40 mg mL\(^{-1}\) of polyampholyte dissolved in cell media (either F12-K or MEM), 10% DMSO, and 10% FBS for 10 min. Polyampholyte solutions were subsequently removed, and the 24 well plates were positioned on a Corning XT CoolSink 96F and placed in a −80 °C freezer overnight. The thermodenuding block ensures well-to-well temperature consistency (no “edge effects”), while eliminating the air gap between the bottom of the well plate and the temperature source. As a control, cells were also cryopreserved as monolayers, in the same manner, with 10% DMSO alone. Cells were removed from the −80 °C, immediately thawed with warm complete cell media (37 °C), and placed in the incubator for 24 h. For variable density freezing, the freezing process was described above, however, cells seeded were serially diluted 2-fold across each column (i.e., 6 times along the six columns). Phase contrast images of nonfrozen and frozen cells were taken on an Olympus CX41 microscope equipped with a UIS-2 20\(\times\)/0.45/∞/0-2/FN22 lens (Olympus Ltd., Southend-on-Sea, U.K.) and a Canon EOS 50D SLR digital camera. Images were processed using ImageJ (v1.52). Following imaging, cells were dissociated with trypsin (0.25%) and EDTA (1 mM), and the suspended cells were stained with trypsin blue to count membrane intact cells. Percentage cell recovery was calculated by comparing cell counts immediately before and 24 h after thawing.

**Bioc hemical Assays.** Various assays were completed as a demonstration of perfect cell heath following freeze-thaw, along with immediate assay-readiness status 24 h post-thaw. The previously described cryopreservation method was used for the banking of cells used throughout.

**Resazurin Cell Viability Assay.** A549 (0−35k cells/well) and HepG2 (0−15k cells/well) cells frozen at multiple densities were thawed with warm complete cell media (37 °C). After 24 h, the media was replaced with resazurin solution (500 μL), which was prepared by dissolving 1 tablet (Scientific 300 Laboratory Supplies, CHE3158) in 50 mL of phenol-free DMEM/F-12. Absorbance measurements were obtained at 570 and 600 nm every 30 min/1 h for 4 h to monitor the reduction of resazurin to resorufin by viable cells. Fluorescence measurements were also recorded using a BioTek Synergy HT microplate reader with a 530/25 nm excitation and 590/35 nm emission filter. Nonfrozen cells were also treated with resazurin (absorbance measurements) or normalized fluorescence intensity, whereby fluorescence measurements were normalized to the starting absorbance at 0 time.
readings obtained with the highest cell density. Resazurin solutions without any cells were used to provide background measurements.

**Live/Dead Assay.** A549 and HepG2 cells frozen as confluent monolayers were thawed with warm complete cell media (37 °C) and, 24 h post-thaw, were stained with ethidium iodide (2 μM) and calcein (2 μM) in phenol-free DMEM/F-12 (100 μL) for 40 min at RT. Cells were imaged with an Olympus CX41 microscope using phase contrast and blue (calcein) and green (ethidium) excitation lasers. Nonfrozen cells were also stained to provide control images. ImageJ was utilized to count live (calcein) and dead (red) cells to determine the percentage of live, membrane intact, cells.

**Caspase-3/7 Real-Time Activation Assay.** A549 and HepG2 cells frozen as confluent monolayers were thawed with warm complete cell media (37 °C). Following 10 min of incubation, the media was replaced with complete media supplemented with CellEvent Caspase-3/7 Detection Reagent (5 μM). Images were taken at 1, 2, 4, and 24 h time intervals on an Olympus CX41 microscope with a phase contrast channel and a blue excitation laser. Cells were counted using ImageJ, and values were reported as percentage caspase positive cells relative to the total number of cells. Nonfrozen cells were also stained with CellEvent Caspase-3/7 Detection Reagent to provide a baseline reading.

**CYP Activity.** HepG2 cells were frozen at a density of 37.5–150k cells per well, as described above, for 24 h. Cells were thawed with warm complete cell media (37 °C) and incubated for 48 h. To determine innate CYP450 activity, CYP3A4 and CYP2C9 were subsequently measured using the corresponding Promega CYP450 kits. Briefly, media were replaced with a culture medium containing a luminogenic CYP substrate, either CYP3A4/Luciferin-IPA (3 μM, 300 μL, 1 h) or CYP2C9/Luciferin-H (100 μM, 300 μL, 3 h). The CYP substrate was also added to empty wells as a background measurement. The culture medium containing the CYP substrate (25 μL) was transferred to an opaque white 96 well plate, and luciferin detection reagent (25 μL) was added for 20 min at RT. Luminescence was measured on a BioTek Synergy HT microplate reader. The CYP activity of nonfrozen cells was also measured for comparison. Nonfrozen and Frozen HepG2 monolayers were also treated with rifampicin (0–100 μM, 48 h), 24 h post-thaw, to induce further CYP activity and measured as described previously.

**Growth Curve.** A549 and HepG2 cells were cryopreserved at a density of 20k and 50k cells/well, respectively, in 24 well plates. Cells were thawed with warm complete cell media (37 °C) and allowed to incubate for 24 h. Cells were counted daily until ~80–90% confluency was reached, with trypan blue used to stain for membrane intact cells, and proliferation rates were determined.

**Testing Drug Screening Capacity.** A549 and HepG2 cells were seeded at the optimum density determined for resazurin assays previously explored (10k and 20k cells per well, respectively), on 24 well plates, taking into consideration proliferation rates and duration of drug screening experiments. Cells were frozen with 40 mg mL⁻¹ of polyampholyte, as described above, and thawed with warm complete cell media (37 °C) after 24 h of storage in a −80 °C freezer. Cells were washed with DPBS, 24 h post-thaw, and incubated with doxorubicin (200–0 μg mL⁻¹) for a further 24 h. Cells were washed with DPBS, and resazurin solutions (500 μL) were added to the cells. Absorbance measurements were obtained at 570 and 600 nm every 30 min/1 h for 4 h to monitor the reduction of resazurin to resorufin by viable cells. Control cells untreated with doxorubicin were also treated with resazurin solutions to provide a maximum resazurin reduction value of viable cells, and resazurin solutions without any cells were used to provide background measurements.

**Cell Cycle Analysis.** A549, HepG2, and Caco-2 cells frozen as confluent monolayers were thawed with warm complete cell media (37 °C) and incubated for 24 h. Cell dissociation was completed using trypsin (0.25%) and EDTA (1 mM) to harvest 1 × 10⁶ cells mL⁻¹. Cells were centrifuged and resuspended in cold 70% ethanol (250 μL), added dropwise while vortexing, and fixed for 30 min at 4 °C. Cells were centrifuged at 300g for 5 min, and the pellet was washed with DPBS. Centrifugation was performed again, and the resulting pellet was resuspended in a solution of DPBS containing 20 μg/mL PI and 100 μg/mL RNase A for 30 min. Nonfrozen cells were also stained for comparative cell cycle measurements. Flow cytometry was performed on a BD Accuri C6 equipped with a 488 nm laser and 585/40, and 50,000 events were recorded. BD CSampler Plus software (v 1.0.34.1) was used for data collection and processing. Cell cycle analysis was completed using ModFit LT v4.0.

**Cell Banking and Transportation Capabilities.** A549 and HepG2 cells were frozen at a density of 200k cells per well, as described above, and stored for 1 month in a −80 °C freezer or for 5 days in dry ice, to determine the potential for long-term storage and transportation, respectively. Cells were thawed with warm complete cell media (37 °C). After 24 h, cells were dissociated with trypsin (0.25%) and EDTA (1 mM), and the suspended cells were stained with trypan blue to count membrane intact cells. Percentage cell recovery was calculated by comparing cell counts immediately before and 24 h after thawing.

**RESULTS AND DISCUSSION**

Our primary aim is to cryopreserve cells in a format that is ready to use directly from a −80 °C freezer, with no additional processing steps, in particular, to remove the need for routine cell handling. Figure 1. The macromolecular cryoprotectant selected to achieve this was a polyampholyte generated by the ring open polymerization of poly(methyl vinyl ether-alt-maleic anhydride) with dimethylamino ethanol, to produce a polymer

![Figure 1. Schematic comparing the processing of cells following cryopreservation in (A) suspension format and (B) an "assay-ready" monolayer format.](https://doi.org/10.1021/acs.biomac.2c00791)
with 1:1 cationic/anionic groups, which has been previously demonstrated to allow the cryopreservation of A549 monolayers.\textsuperscript{54} The proposed workflow for the cryopreservation and recovery of cell monolayers is displayed in Figure 2A. Briefly, cells seeded in 24 well plates were incubated with CPAs (40 mg mL\textsuperscript{−1} of polyampholyte and 10\% (v/v) DMSO) at RT for 10 min. The CPAs were subsequently removed so that only a thin coating remains, and the well plate was placed onto a thermoconductive block in a −80 °C freezer. As part of the process, the excess cryoprotectant is removed before freezing to reduce any potential cytotoxicity from the cryoprotectants, increase freezing rates and facilitate the thawing process. Acker and Mcgann previously confirmed that rapid freezing by removing CPA is beneficial to the freezing process, the excess cryoprotectant is removed before thawing process.\textsuperscript{47} Post-thaw cell recovery of HepG2 monolayers cryopreserved with 10\% DMSO alone only achieved an average cell recovery of 49.9\% across all cell types, Figure S5. The abnormally high cell recovery values for DMSO alone, compared to previously reported literature values (≤30\%),\textsuperscript{50} reflect the optimization of the freezing protocols, which, together with the selection of cryoprotectant, is crucial for the successful cryopreservation of nucleated cells. The minimal handling required to obtain high post-thaw cell recovery values shows the remarkable potency of polyampholyte as a cryoprotectant, transforming sub-useful cell recovery levels to near-quantitative. For comparison, proline preconditioning of A549 cells only achieves a post-thaw cell recovery of ∼50\% for the cryopreservation of monolayers\textsuperscript{35} and the post-thaw recovery of HepG2 monolayers cryopreserved in trehalose supplemented solutions is 42\%.\textsuperscript{47} Thus, this polyampholyte can protect cell lines that are routinely difficult to cryopreserve for the future banking of cell libraries. As a note, HepG2 and Caco-2 cells required collagen-coated plates to ensure high cell recovery values (Figure S18) by promoting adhesion to the substrate during freezing. To demonstrate reproducibility, two independent researchers were able to freeze six 24 well plates containing cell monolayers with no impact to cell recovery values, Figure S7.

Rather than aggregated cell data across the entire plate, the cell recovery values for a selection of individual wells have also been reported (along with individual repeat values) to exaggerate any variance between wells, Figure 2B. Regardless of the cell type, minimal well-to-well variance was found in the mean cell recovery values, a crucial factor in screening assays where there must be confidence that results aren’t artificially increased or decreased due to variability in cell density across the well plate.

Varying cell seeding densities (12.5k–100k cells per well) also had no influence on the cryopreservation outcome, with over 75\% of cells recovered 24 h post-thaw, Figure 3A. Cryopreservation studies focus on confluent cell monolayers, as the general belief is that higher recovery values can be
However, for cell viability assays, a linear response between cell seeding density and signal output (usually absorbance or fluorescence) is required to ensure that cell viability can be accurately determined. Thus, the ability to cryopreserve cells at multiple cell seeding densities is crucial for assay development and toxicological screening assays. A resazurin reduction metabolic assay was completed on nonfrozen and frozen A549 and HepG2 cells, plated at varying seeding densities, to determine the quantity of cells required to freeze to ensure a linear output with resazurin reduction to resorufin and, thus, allow its use for drug screening, see below.

Optical microscopy images taken of nonfrozen cells and cells frozen with both polyampholyte and DMSO, shown in Figure 4, illustrate that post-thaw cell morphology is normal and unaffected by the freezing process. A549 and HepG2 cells remained adhered to the well plate, and confluent monolayers were observed. Optical microscopy images were also taken of cells frozen at different cell densities (Figure S8). Again, cells appeared healthy regardless of cell density and were ready for use within the 24 h recovery time provided. Cryopreservation with DMSO alone resulted in spherical cell morphologies associated with unhealthy cells. The injury phenotype has previously been characterized as intracellular freezing damage, indicated by the dark cytosol and disruption of intercellular networks.

Standard rapid freezing methods increase the likelihood of IIF by reducing cell dehydration. Cryomicroscopy images of A549, HepG2, and Caco-2 cells, Figure S12, confirmed the presence of IIF during freezing (darkening of the cytosol); however, cells preincubated with both polyampholyte and DMSO have a lower surface area compared to DMSO alone (Figures S12 and S13), suggesting that polyampholyte can aid in cellular dehydration as part of their mechanisms of action. Thus, the polyampholyte is not acting to completely remove IIF but to minimize the damage caused by it, so that the intracellular ice formed can be considered innocuous.

Optical microscopy images were also taken of post-thaw confluent A549 and HepG2 cells from different positions within a single well, to illustrate the low intra-well variance obtained using polyampholyte and DMSO, Figure 5. Cell morphology remained consistently healthy across the different positions. In the case of HepG2, fewer cells were observed in position 1 compared to the other 2 positions. The variation in cell number is likely due to natural variation from the initial seeding process, where traditional seeding methods can result in increased cell aggregation across the circumference and/or the center of wells compared to other positions.

Confluent monolayers were observed in all other positions for both A549 and HepG2 cells.
cryopreserved with 10% v/v DMSO and 40 mg mL\textsuperscript{-1} polyampholyte, were taken at 3 positions within an individual well. Scale bar = 100 μm.

To evaluate the quality of the cells post-thaw, a panel of further assays was undertaken. Membrane integrity is a general measure of post-thaw recovery and is a vital assessment for the health of liver cell lines, as enzyme leakage would be detrimental to enzyme activity assays used in hepatotoxicity screening for the identification of bioactive drugs and their potential mechanisms.\textsuperscript{68,69} A549 and HepG2 cells, both nonfrozen and post-thaw, were stained with calcein (green, healthy, intact membrane) and ethidium iodide (EI, red, dead, damaged membrane) to visualize the presence of membrane damage, Figure 6A. Microscopy images immediately revealed few red, EI-positive cells in both nonfrozen and frozen cells, indicating minimal membrane damage. Quantification of the percentage of live cells (i.e., stained positive for calcein), relative to the total number of cells from images, was completed to compare membrane-damaged cells between nonfrozen and frozen cells, Figure 6B. Although a statistically significant decrease in membrane intact cells was observed in cells post-thaw, intact levels remained at ∼96% for A549 cells and ∼88% for HepG2 cells. The absence of membrane damage confirms that physical disruption of cells is avoided during cryopreservation with polyampholyte and DMSO, which reduces the likelihood of necrosis cell death and the risks of introducing bias in any downstream functional assay.

Programed cell death (e.g., apoptosis) pathways were also investigated as cryopreservation can activate intrinsic, extrinsic, and calpain apoptosis pathways.\textsuperscript{70–72} Hypothermic solutions and general caspase and ROCK inhibitors (apoptotic inhibitors) have been used to reduce post-thaw apoptotic cells.\textsuperscript{70,73,74} Due to the importance of apoptosis in cryopreservation outcomes, the induction of executioner caspases 3 and 7 (cysteinyl aspartate-specific proteases) in post-thaw confluent A549 and HepG2 cell monolayers was monitored by fluorescence microscopy to visualize the appearance of apoptotic cells over time, Figures 7A and S14. Minimal caspase-3/7 positive cells (green) were observed in microscopy images at all timepoints within the 24 h imaging period. The percentage of caspase-3/7 positive cells relative to the total number of cells present was quantified, Figure 7B, confirming that apoptotic cells were maintained below 10% following freeze/thaw. Apoptotic inhibitors have previously been used to minimize apoptosis following the cryopreservation of mesenchymal stem cells due to the high apoptosis levels (∼40%).\textsuperscript{70} Our system offers cryopreserved monolayer cells with substantially lower apoptosis rates for the cell lines selected, thus the introduction of apoptosis inhibitors would provide minimal benefits. The post-thaw recovery time selected (24 h) is underpinned by these results, to enable apoptotic events to occur and minimize the potential for false-positive results that occur when immediate post-thaw recovery/viability is reported.\textsuperscript{6}

Membrane permeability and apoptosis measurements offer an assessment of immediate cell health post-thaw; however, growth curve measurements are required to determine if cells are healthy long-term. Nonfrozen and post-thaw cells were counted daily, until 80–100% confluency was reached, to determine if the proliferation times of monolayer frozen cells were affected by the freeze/thaw process and have been reported in Figure 8. No significant difference was found between the doubling time of A549 cells before and after freezing; however, HepG2 doubling time increased from 29 to 38 h. Despite this, HepG2 doubling rates of 48 h have been reported, and our lab has also experienced similar doubling rates, so the proliferation rate of post-thaw HepG2 cells is within the normal range expected.\textsuperscript{75}

Cryopreservation may significantly alter cell cycle populations up to 48 h post-thaw; however, there are limited reports on this.\textsuperscript{76} Previous cell recovery and viability measurements confirm that, after freezing, cells maintain a “healthy” state, but gaining information into cell cycle population distributions offers additional insight into proliferation capacity,\textsuperscript{77} apoptotic

Figure 5. Phase contrast images of A549 and HepG2 monolayers, cryopreserved with 10% v/v DMSO and 40 mg mL\textsuperscript{-1} polyampholyte, were taken at 3 positions within an individual well. Scale bar = 100 μm.

Figure 6. Membrane integrity assessment of cryopreserved cell monolayers. (A) A549 and HepG2 cells were stained with calcein (green, intact membrane) and EI (red, damaged membrane) 24 h following freeze/thaw and imaged. Nonfrozen cells were also stained for comparison. Scale bar = 100 μm. (B) Average percentage of membrane intact (calcein positive) A549 and HepG2 cells were determined before (dark grey bar) and 24 h post-thaw (light grey bar) ± SEM of 2 independent repeats (ANOVA, Tukey PostHoc; *p ≤ 0.05, **p ≤ 0.001).
cells, and cells undergoing repair processes. Cell cycle population distributions were measured by univariate analysis of cellular DNA following propidium iodide staining, flow cytometry, and deconvolution of the cellular DNA content frequency histograms. Histograms can be found in the Supporting Information, Figure S15, and the cell cycle populations have been reported in Table 1. Apoptotic cells were not observed in the cell cycle histograms, which are usually present in the sub G0/G1 fluorescence range (due to loss of DNA content). The majority of A549 and Caco-2 cells were either in the S or G2/M phase, a clear distinction from HepG2 cells, which is considered an indicator for increased proliferative potential. Post-thaw, all cell types experienced a decrease in G0/G1 cells and an increase in S-phase cells, a clear indicator that cells are not in G0/G1 arrest (apoptosis indicator) and retain proliferative capacity. A549 and Caco-2 cells retained similar cell cycle population distributions before and after freezing (24 h post-thaw), whereas clear differences were observed with HepG2 cells which could reflect the changes in proliferation rates between nonfrozen and frozen HepG2 cells previously observed. Regardless, proliferative capacity was retained for all cell types, with minimal indicators of apoptosis found, confirming that cells are functional for use following freeze/thaw.

A primary aim of this research program was to provide a scalable method of freezing cells in the monolayer format for use in screening applications, eliminating the need for extensive cell culturing and handing. Obtaining dose–response information, which involves the core principles of pharmaco-kinetics and pharmacodynamics, is essential for drug screening, to determine the required drug dosage and frequency, as well as its therapeutic index. Thus, a proof-of-concept drug screening experiment was carried out with doxorubicin (a chemotherapeutic) using the previously optimized resazurin reduction cell viability assay. The drug screening workflow is illustrated in Figure 9A. Briefly, cells were cryopreserved, using our system, at the optimal density required to ensure accurate % cell viability calculations. Following 24 h storage, cells were thawed with warm complete cell media and incubated for 24 h, and doxorubicin solutions were added (0–200 μg mL⁻¹) for 24 h. Resazurin solutions were subsequently added, and the reduction of resazurin to resorufin was measured at 570 and 600 nm to calculate percentage cell viability and generate dose–response curves, Figure 9B. A sigmoidal relationship was found between log₁₀ of doxorubicin concentrations and % cell viability, with plateaus at the bottom and top of the response, allowing the accurate determination of doxorubicin’s IC₅₀ value (the concentration of doxorubicin required to reduce cell viability to 50%). HepG2 cells are the most widely used line for the toxicological screening of new drugs and are currently deployed in automated/high throughput systems. The ability to generate dose–response curves and calculate

**Table 1. Cell Cycle Analysis From Flow Cytometry**

<table>
<thead>
<tr>
<th></th>
<th>G0/G1 (%)</th>
<th>G2M (%)</th>
<th>S-phase (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A549. nonfrozen</td>
<td>28.0</td>
<td>4.6</td>
<td>67.5</td>
</tr>
<tr>
<td>A549. post-thaw</td>
<td>21.5</td>
<td>1.5</td>
<td>77.0</td>
</tr>
<tr>
<td>HepG2. nonfrozen</td>
<td>68.5</td>
<td>22.4</td>
<td>9.1</td>
</tr>
<tr>
<td>HepG2. post-thaw</td>
<td>54.8</td>
<td>12.8</td>
<td>32.4</td>
</tr>
<tr>
<td>Caco-2. nonfrozen</td>
<td>43.1</td>
<td>8.0</td>
<td>48.9</td>
</tr>
<tr>
<td>Caco-2. post-thaw</td>
<td>39.5</td>
<td>8.0</td>
<td>52.5</td>
</tr>
</tbody>
</table>
IC$_{50}$ values using monolayer cryopreserved cells confirms their suitability for drug screening applications, finding biologically active compounds, and providing a way to increase automation through minimal cell-handling procedures.

HepG2 cytochrome p450 (CYP) activity was also assessed between nonfrozen and monolayer preserved cells 24 h post-thaw, Figure S16. CYP enzymes are vital in drug metabolism, with CYP3A4 being responsible for 50% of all drug metabolism.$^{81}$ Thus, many drug screening applications rely on monitoring the inhibition of CYP enzymes, which could slow drug metabolism time resulting in undesired drug−drug interactions.$^{82,83}$ Although insignificant, CYP3A4 activity of cells post-thaw was slightly suppressed post-thaw compared to nonfrozen cells, whereas CYP2C9 levels remained either unaffected or marginally higher. The innate expression of CYP enzymes was low for HepG2 cells and remained low even with the use of an inducer (rifampicin), Figure S17, which is consistent with previous studies.$^{84}$ The selection of future cells with greater response to CYP inducers, with improved predictability for human hepatotoxin detection, will be explored to expand our library of cryopreserved monolayer cells. However, the data presented here clearly demonstrates that HepG2 monolayers can be cryopreserved in an assay-ready format, potentially enabling the first direct from storage to automated screening platform.

To ensure that a sustainable supply of monolayer cryopreserved cell lines is possible, the long-term storage of cells is required. Although cells cryopreserved in suspension can be stored long-term at temperatures less than or equal to −80 °C, retaining >90% viability post-thaw,$^{8,85}$ no reports were found on the medium-to-long term storage of cells cryopreserved as monolayers in a −80 °C freezer. Confluent A549 and HepG2 monolayers were cryopreserved as previously described and stored for 1 month in a −80 °C freezer. Optical microscopy images were taken of the confluent monolayers directly before freezing and 24 h post-thaw, Figure 10A. No changes to cell morphology were observed post-thaw and cells remained as confluent monolayers. A decrease in % cell recovery was found following long-term storage suggesting there may be some cell detachment during thawing or cell death, Figure 10B. However, no cell debris was found, and a cell recovery of ~70% was obtained, which is sufficient to allow cells to be used for desired applications. Longer-term storage could be improved by conventional liquid N$_2$ methods. Cells were also stored in dry ice for over 5 days, with no significant decrease in cell recovery (Figure S18), which provides a route for the transportation of cryopreserved plated cell monolayers.

### CONCLUSIONS

Here we introduce truly “assay-ready” cryopreserved adherent cells, ready to be used directly from a freezer within industry standard microplates, removing the need for standard handling, manipulations, management, and other time- and resource-expensive activities associated with cell culture and biomedical testing. This overcomes a historical challenge and perception that cells cannot be stored and distributed in monolayer format. The key component to enable such reproducible monolayer freezing was the use of a synthetic polyampholyte which, when used alongside the standard CPA DMSO, leads to dramatic increases in post-thaw cell yield and viability of up to 93%, compared to ~50% using DMSO alone. Initial data

---

**Figure 9.** Post-thaw drug screening tests on cryopreserved cell monolayers. (A) Schematic of the drug screening process used on cryopreserved monolayers. (B) Cell viability of A549 (black) and HepG2 (blue) monolayers was monitored by resazurin reduction following treatment with doxorubicin (0−250 μg mL$^{-1}$, 24 h). Percentage cell viability was calculated relative to an untreated control sample ± SEM from 2 independent repeats.

**Figure 10.** Long-term storage of cryopreserved cell monolayers. (A) Optical microscopy images were taken of A549 and HepG2 cell monolayers before freezing and 24 h post-thaw following 1 month of storage in a −80 °C freezer. Scale bar = 100 μm. (B) Average percentage cell recovery of A549 (white bar) and HepG2 (grey bar) cell monolayers following 1 and 30 days of storage in a −80 °C freezer were reported ± SEM from 2/3 independent repeats (ANOVA, Tukey PostHoc; ns: $p > 0.05$,$^*$ $p \leq 0.05$).
suggests that the polyampholyte supports the cellular dehydration process during freezing, reducing the damaging effects of IIF. In addition to the macromolecular cryoprotectant, the freezing and thawing conditions were optimized to minimize well-to-well variance, ensuring homogenous cell recovery within and between microplates. Successful monolayer cryopreservation was demonstrated for A549, HepG2, and Caco-2 cells, representing a diverse range of commonly used cell lines within biomedical research and toxicology testing. To confirm that the cells were functional and healthy, a large panel of assays was undertaken. Post-thaw membrane damage and necrosis indicators were kept minimal and only a small increase in cells displaying apoptosis markers was observed. Cell cycle analysis and post-thaw growth curves confirmed that cells retained proliferative capacity. Cryopreserved A549 and HepG2 cell monolayers were subjected to a model assay development and toxicological challenge, to demonstrate that the cells are truly “assay ready” 24 h post-thaw and can be used for the testing of pharmaceutically active compounds. Overall, we have demonstrated that cells can be cryopreserved as “assay-ready” monolayers, in a scalable and versatile manner, which will enable the development of new screening technologies, enhance automation, and reduce the experimental burden on researchers.

DATA ACCESS STATEMENT

The research data supporting this publication is found in the Supporting Information and any additional data can be found at http://wrap.warwick.ac.uk.

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.biomac.2c00791.

Polymer characterization data; additional cell recovery data, live/dead images and caspase images; resazurin cell viability assay development; growth curve measurements; cell cycle flow cytometry histograms; HepG2 cytochrome p450 activity assays; cell recovery after dry ice storage; and cryomicroscopy images (PDF)

AUTHOR INFORMATION

Corresponding Author

Matthew I. Gibson — Department of Chemistry and Division of Biomedical Sciences, Warwick Medical School, University of Warwick, Coventry CV4 7AL, U.K.; orcid.org/0000-0002-8297-1278; Email: m.i.gibson@warwick.ac.uk

Authors

Ruben M. F. Tomás — Division of Biomedical Sciences, Warwick Medical School, University of Warwick, Coventry CV4 7AL, U.K.

Akalabya Bissoyi — Division of Biomedical Sciences, Warwick Medical School, University of Warwick, Coventry CV4 7AL, U.K.


Complete contact information is available at: https://pubs.acs.org/10.1021/acs.biomac.2c00791

References


(14) Gómez, S.; Del Mont Llosas, M.; Verdú, J.; Roura, S.; Lloreta, J.; Fabre, M.; García De Herreros, A. Independent Regulation of


